NEOPLASMS

This study tested two drugs, brigimadlin and ezabenlimab, in adults with advanced solid tumors. The first part found the safest dose, and the second part checks if the combination can shrink tumors. Participants take pills and get infusions every 3 weeks for up to 2 years, as lon…

This early-phase study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and how the drug moves through the body. This is n…

This early-phase study tested a new drug called MK-4830, either alone or combined with other cancer treatments like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety and see if tumors shrank. This is not a cure, but aims to control the d…

This study tested a combination of two drugs (BI 836880 and ezabenlimab) in adults with advanced lung cancer and other solid tumors. The first part found the safest dose, and the second part checked if the combo could shrink tumors. Participants received infusions every 3 weeks a…

This early-phase study tested a new drug called vibostolimab, either alone or combined with pembrolizumab (and sometimes chemotherapy), in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right…

This study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival over time. The goal was to see if continuing the drug was safe and benefi…

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for each combination to use in later studies. Participant…

This study tested a new cancer drug called brigimadlin in 266 adults with advanced solid tumors that had spread. The goal was to find a safe dose and see if the drug could shrink tumors. Participants took the drug as a tablet on different schedules and stayed in the study as long…

This early-phase trial tested a new drug called BI 836880 in 29 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and watch for side effects. The study was not designed to cure the cancer, but to gather inf…

This early-stage study tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers monitored side effects and how the dr…

This early-phase trial tested a new drug called BI 836880 in 24 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Participants received the drug once a week through an IV. Th…

This early-phase trial tested a new drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This early-stage study tested a new drug, JNJ-70218902, that helps the body's immune T cells attack cancer. It involved 82 people with advanced solid tumors, including prostate cancer that had spread. The main goals were to find the safest dose and check for side effects.

This early-phase trial tested a drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if TdCyd is safe and can help turn back on genes that slow tumor growth. Participants took the drug in 3-week cycles a…

This early-phase trial tested a new drug called BI 754091 in 110 adults with advanced solid tumours that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. Researchers also looked for signs that the drug might sh…

This small pilot study tested a device called NaviFUS that uses focused ultrasound waves, combined with the standard drug bevacizumab, in 6 adults whose glioblastoma brain tumor had returned after prior treatment. The goal was to see if the combination was safe and could help con…

This study tested two experimental drugs, BI 754111 and BI 754091, that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This early-phase study tested a new drug (BI 836880) alone or combined with another drug (BI 754091) in 21 Japanese adults with advanced solid tumours. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling a…

This early-phase study tested the safety of combining two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard treatments. Participants received the drugs in 21-day cycle…

This study tested a radioactive drug called 177Lu-NeoB in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to see if the drug is safe, how it spreads in the body, and if it can shrink tumors. Participants had no other standard treatment option…

This early-phase study tested two experimental drugs (BI 754091 and BI 754111) alone or together in 146 Asian patients with advanced solid tumours. The goal was to find safe doses and check for early signs of tumour shrinkage. The study is complete, but results are not yet public…

This study tested a new pill called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. The goal was to see if it could shrink enlarged spleens and reduce the need for blood transfusions. The drug was given alone or with another medicine (ruxoli…

This early-stage study tested a new drug called JNJ-64619178 in 114 adults with advanced cancers (like lymphoma, solid tumors, or myelodysplastic syndromes) that had not responded to other treatments. The main goal was to find the safest dose and check for side effects. The drug …

This early-phase study tested a new treatment called RD13-02, which uses a patient's own immune cells modified to attack cancer cells with a specific marker (CD7). It involved just 2 people with blood cancers like T-cell acute lymphoblastic leukemia that had come back or not resp…

This early-phase trial tested two experimental drugs taken by mouth—FdCyd and THU—in 59 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the combination could control tumor growth. Participants took …

This study tested a special pad (PadKit™) worn for 4-6 hours to collect cells shed from the uterus. Researchers checked if the pad could tell the difference between normal cells and cancer or precancerous cells. 80 women scheduled for surgery took part. The goal was to see if thi…

This study tested a new device called PointCheck that uses light to check for dangerously low white blood cell levels (neutropenia) in cancer patients without needing a needle. 81 cancer patients receiving chemotherapy were enrolled. The main goal was to see how easy the device i…

This study tested whether advanced PET-MRI scans can find prostate cancers that standard MRI might miss. 62 men who were considering focal therapy or prostate removal took part. The goal was to see if the new imaging could better map the cancer and help guide treatment decisions.

This study looked at whether a program called expressive helping—where people write or record their thoughts and feelings—is practical and helpful for Chinese-speaking cancer patients and survivors. Sixty adults with any type of cancer took part. The goal was to see if the progra…

This study tested whether a mobile app could help cancer patients recognize and report treatment side effects more effectively. 222 adults receiving chemotherapy or radiation therapy used the app to track their symptoms. The goal was to improve communication with doctors and help…

This study looked at whether a mix of in-person and online physiotherapy sessions is practical for children aged 4 to 17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which used an online platform for exercises and education. The goal was to…

This study looked at how often cancer patients develop dangerous blood clots, especially those who also have bleeding problems or take blood thinners. Researchers followed 700 hospitalized cancer patients to track clot rates and understand risk factors. The goal was to gather inf…

This study tested a financial navigation program for 258 cancer patients in rural and non-rural North Carolina clinics. The goal was to see if helping patients manage costs could reduce financial toxicity and improve quality of life. Participants had high financial distress and r…

This study tested whether iPhones and Apple Watches can help monitor symptoms and activity levels in people with cancer. 49 adults receiving cancer treatment at the NIH wore an Apple Watch and used an iPhone for 4 months. The goal was to see if these devices could reliably measur…

This study looked at 33 adults who had both cancer and a low platelet condition called immune thrombocytopenia (ITP). Researchers wanted to see if cancer cells might confuse the immune system into attacking platelets. The goal was to understand this link better, not to test a new…

This study looked at over 200,000 adults with obesity and type 2 diabetes to see if the type of diabetes medication they took before a cancer diagnosis affected their survival and health after cancer. Researchers compared GLP-1 receptor agonists (like Ozempic) with other diabetes…

This study tested whether a computer could learn to recognize cancer pain by analyzing people's facial expressions and voices. 83 people with cancer recorded short videos at the clinic and at home over three months. The goal was to see if this technology could be a useful tool fo…

This study tested a mobile program designed to help young adult cancer survivors (ages 18-39) eat healthier and be more physically active. 72 survivors joined the pilot trial to see if the program was easy to use and liked by participants. The goal was to learn if this approach c…